Advances in the development of biomarkers for epilepsy DOI
Asla Pitkänen, Wolfgang Löscher, Annamaria Vezzani

и другие.

The Lancet Neurology, Год журнала: 2016, Номер 15(8), С. 843 - 856

Опубликована: Июнь 6, 2016

Язык: Английский

Blood-Brain Barrier: From Physiology to Disease and Back DOI Open Access
Melanie D. Sweeney, Zhen Zhao, Axel Montagne

и другие.

Physiological Reviews, Год журнала: 2018, Номер 99(1), С. 21 - 78

Опубликована: Окт. 3, 2018

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and pathogens from entering the brain. At same time, BBB regulates transport of molecules into out central nervous system (CNS), which maintains tightly controlled chemical composition neuronal milieu that is required for proper functioning. In this review, we first examine molecular cellular mechanisms underlying establishment BBB. Then, focus on physiology, endothelial pericyte transporters, perivascular paravascular transport. Next, discuss rare human monogenic neurological disorders with primary genetic defect in BBB-associated cells demonstrating link between breakdown neurodegeneration. review effects genes inheritance and/or increased susceptibility Alzheimer's disease (AD), Parkinson's (PD), Huntington's disease, amyotrophic lateral sclerosis (ALS) relation to other pathologies deficits. We next how dysfunction relates deficits majority sporadic AD, PD, ALS cases, multiple sclerosis, neurodegenerative disorders, acute CNS such as stroke, traumatic brain injury, spinal cord epilepsy. Lastly, BBB-based therapeutic opportunities. conclude lessons learned future directions, emphasis technological advances investigate functions living brain, at level, address key unanswered questions.

Язык: Английский

Процитировано

1691

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders DOI
Orrin Devinsky, Maria Roberta Cilio, J. Helen Cross

и другие.

Epilepsia, Год журнала: 2014, Номер 55(6), С. 791 - 802

Опубликована: Май 22, 2014

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance epilepsy and other selected neuropsychiatric disorders. We summarize presentations from conference in which invited participants reviewed relevant aspects physiology, mechanisms action, pharmacology, data studies animal models human subjects. Cannabis has been used treat disease since ancient times. Δ(9) -Tetrahydrocannabinol (Δ(9) -THC) is major psychoactive ingredient CBD nonpsychoactive cannabis. -THC are anticonvulsant most but can be proconvulsant some healthy animals. The psychotropic effects limit tolerability. many acute models, there limited chronic models. antiepileptic not known, may include on equilibrative nucleoside transporter; orphan G-protein-coupled receptor GPR55; transient potential vanilloid type-1 channel; 5-HT1a receptor; α3 α1 glycine receptors. neuroprotective antiinflammatory effects, it appears well tolerated humans, small methodologically have inconclusive. More recent anecdotal reports high-ratio CBD:Δ(9) medical marijuana claimed efficacy, were controlled. bears investigation disorders, including anxiety, schizophrenia, addiction, neonatal hypoxic-ischemic encephalopathy. However, we lack well-powered double-blind randomized, controlled efficacy pure for any disorder. Initial dose-tolerability focusing target intractable populations such as patients Dravet Lennox-Gastaut syndromes being planned. Trials treatment-resistant epilepsies also warranted. A PowerPoint slide summarizing this article available download Supporting Information section here.

Язык: Английский

Процитировано

933

Blood–brain barrier structure and function and the challenges for CNS drug delivery DOI
N. Joan Abbott

Journal of Inherited Metabolic Disease, Год журнала: 2013, Номер 36(3), С. 437 - 449

Опубликована: Апрель 22, 2013

Язык: Английский

Процитировано

804

Glia and epilepsy: excitability and inflammation DOI
Orrin Devinsky, Annamaria Vezzani, Souhel Najjar

и другие.

Trends in Neurosciences, Год журнала: 2013, Номер 36(3), С. 174 - 184

Опубликована: Янв. 5, 2013

Язык: Английский

Процитировано

770

Epilepsy DOI
Orrin Devinsky, Annamaria Vezzani, Terence J. O’Brien

и другие.

Nature Reviews Disease Primers, Год журнала: 2018, Номер 4(1)

Опубликована: Май 3, 2018

Язык: Английский

Процитировано

732

Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy DOI
Annamaria Vezzani, Silvia Balosso, Teresa Ravizza

и другие.

Nature Reviews Neurology, Год журнала: 2019, Номер 15(8), С. 459 - 472

Опубликована: Июль 1, 2019

Язык: Английский

Процитировано

671

New avenues for anti-epileptic drug discovery and development DOI
Wolfgang Löscher, Henrik Klitgaard, Roy E. Twyman

и другие.

Nature Reviews Drug Discovery, Год журнала: 2013, Номер 12(10), С. 757 - 776

Опубликована: Сен. 20, 2013

Язык: Английский

Процитировано

629

Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation DOI Creative Commons
Bruno Lima Giacobbo, Janine Doorduin, Hans Klein

и другие.

Molecular Neurobiology, Год журнала: 2018, Номер 56(5), С. 3295 - 3312

Опубликована: Авг. 17, 2018

Brain-derived neurotrophic factor (BDNF) is one of the most studied neurotrophins in healthy and diseased brain. As a result, there large body evidence that associates BDNF with neuronal maintenance, survival, plasticity, neurotransmitter regulation. Patients psychiatric neurodegenerative disorders often have reduced concentrations their blood A current hypothesis suggests these abnormal levels might be due to chronic inflammatory state brain certain disorders, as neuroinflammation known affect several BDNF-related signaling pathways. Activation glia cells can induce an increase pro- antiinflammatory cytokines reactive oxygen species, which lead modulation function neurotoxicity observed pathologies. Understanding how involved brain, especially disease onset progression, crucial for development new strategies treatment. Despite increasing involvement scarce addresses interaction between neurotrophin diseases. This review focuses on effect acute inflammation common aims shed some light possible biological mechanisms may influence this effect. In addition, will address behavior pharmacological interventions disorders.

Язык: Английский

Процитировано

614

The role of inflammation in the development of epilepsy DOI Creative Commons

Amna Rana,

Alberto E. Musto

Journal of Neuroinflammation, Год журнала: 2018, Номер 15(1)

Опубликована: Май 15, 2018

Epilepsy, a neurological disease characterized by recurrent seizures, is often associated with history of previous lesions in the nervous system. Impaired regulation activation and resolution inflammatory cells molecules injured neuronal tissue critical factor to development epilepsy. However, it still unclear as how that unbalanced inflammation contributes Therefore, one goals epilepsy research identify elucidate interconnected pathways systemic disorders may further develop progression. In this paper, molecules, (rheumatoid arthritis, Crohn’s, Type I Diabetes, etc.) could contribute development, are reviewed. Understanding neurobiology epileptogenesis will new biomarkers for better screening patients at risk therapeutic targets both prophylaxis treatment

Язык: Английский

Процитировано

572

Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability DOI
Annamaria Vezzani, Barbara Viviani

Neuropharmacology, Год журнала: 2014, Номер 96, С. 70 - 82

Опубликована: Ноя. 8, 2014

Язык: Английский

Процитировано

560